Kymera Therapeutics, Inc. (KYMR) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite a 20% revenue increase, the widening net loss and increased expenses are concerning. The lack of discussion on strategic initiatives or risk management in the earnings call suggests uncertainty. However, the stable cash position and growth in collaboration revenue provide a balanced outlook. Given the market cap of $1.85 billion, the stock is likely to see limited movement, resulting in a neutral prediction.
Key Financial Performance
Revenue Kymera Therapeutics reported revenue of $25 million for Q1 2026, representing a 20% increase year-over-year. This growth was attributed to higher collaboration revenue from partnerships.
Research and Development (R&D) Expenses R&D expenses were $45 million, up 15% compared to the same period last year. The increase was driven by expanded clinical trial activities and investment in pipeline programs.
General and Administrative (G&A) Expenses G&A expenses totaled $12 million, reflecting a 10% rise year-over-year. This was due to higher personnel costs and infrastructure investments.
Net Loss The company reported a net loss of $32 million, which widened by 8% compared to Q1 2025. The increase in net loss was primarily due to higher operating expenses.
Cash and Cash Equivalents Kymera ended the quarter with $300 million in cash and cash equivalents, a decrease of 5% from the previous year. The decline was attributed to increased spending on R&D and operational activities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Abrahams RBC
Amin Piper
Bank PLC
Barclays Bank
Biren Amin
Bradley Canino
Brian Abrahams
Bruce Jacobs
Catanzaro Mizuho
Cheng JPMorgan
Chief
Citigroup Inc
Co Research
Cowen Research
Division Alexander
Division Biren
Division Bradley
Division Catanzaro
Division EDT
Division Jeet
Division Lut
Division Marc
Division Nishant
Inc Research
Instructions
Investor Relations
LLC Research
Officer
President Investor
Research Division
Vice President
KYMR Transcript
Kymera Therapeutics, Inc. (KYMR) Q1 2026 Earnings Call Transcript
Unknown4-30
Despite a 20% revenue increase, the widening net loss and increased expenses are concerning. The lack of discussion on strategic initiatives or risk management in the earnings call suggests uncertainty. However, the stable cash position and growth in collaboration revenue provide a balanced outlook. Given the market cap of $1.85 billion, the stock is likely to see limited movement, resulting in a neutral prediction.
Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-12
Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Kymera Therapeutics, Inc. (KYMR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Neutral12-3
KYMR Slides
KYMR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
